πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

9,250 results for β€œIO” Clear

  1. PEMETREXED , KEYTRUDA 25 mg/mL concentrate for solution for infusion, PACLITAXEL ALBUMIN-BOUND, CARBOPLATIN , PACLITAXEL , pembrolizumab, CISPLATIN

    Merck Sharp and Dohme

    Metastatic (stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).

    phase 3 small molecule active

    1 trial

  2. PEMETREXED , KEYTRUDA 25 mg/mL concentrate for solution for infusion., CARBOPLATIN

    Pari Pharma GmbH

    Adult patients with stage IV non squamous non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  3. PEMETREXED, PEMBROLIZUMAB, CISPLATIN, PACLITAXEL, PACLITAXEL ALBUMIN-BOUND, CARBOPLATIN

    Ningbo Cancer Hospital

    Advanced (stage IIIB/IIIC/IV) NSCLC patients eligible for treatment with a PD-1 antagonist (pembrolizumab) according to the European Marketing Authorisation in a first line

    phase 3 small molecule active

    1 trial

  4. PENTHROX 99,9%, liquide pour inhalation par vapeur de 3 mL, MORPHINE

    Pari Pharma GmbH

    Acute Myocardial Infarction

    phase 3 small molecule active

    1 trial

  5. PF-06651600 Induction Dose

    Pfizer

    Alopecia Areata

    phase 3 small molecule completed

    1 trial

  6. PF-06821497, Tablet to match Placebo for PF-06821497 250mg, PF-06821497, ENZALUTAMIDE, Tablet to match Placebo for PF-06821497 125mg

    Pfizer Australia Pty Ltd

    METASTATIC CASTRATION RESISTANT PROSTATE CANCER

    phase 3 small molecule active

    1 trial

  7. PF614 capsule

    Ensysce Biosciences

    Postoperative Pain, Acute

    phase 3 small molecule active

    1 trial

  8. PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , NEGABAN 2 g, poudre pour solution injectable/pour perfusion, MEROPENEM ARROW 1 g, poudre pour solution injectable / pour perfusion

    Pari Pharma GmbH

    patients hospitalized in ICU with ESBL-producing Enterobacteriaceae severe infection

    phase 3 small molecule active

    1 trial

  9. PIPERACILLINE TAZOBACTAM VIATRIS 4 g/0,5 g, poudre pour solution pour perfusion, CEFAZOLIN, Placebo de Cefazoline / Piperaciline / Tazobactam

    Pari Pharma GmbH

    Excision-autograft surgery in burn patient

    phase 3 small molecule active

    1 trial

  10. PL1 - Lyophilisate and solvent for solution for injection, sotatercept

    Lacuna Pharma Pty Ltd

    Pulmonary Arterial Hypertension (PAH)

    phase 3 small molecule active

    1 trial

  11. PL1 - Placebo to match losmapimod tablets are tablets for oral administration and visually match the active losmapimod tablets, 15 mg., Losmapimod

    Fulcrum Therapeutics

    Facioscapulohumeral Muscular Dystrophy (FSHD)

    phase 3 small molecule active

    1 trial

  12. PL2200 Aspirin Capsules

    Protalix BioTherapeutics

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    2 trials

  13. PLACEBO OF BELIMUMAB, Benlysta 200 mg solution for injection in pre-filled pen.

    Pari Pharma GmbH

    Adult patients with persistent or chronic immune thrombocytopenia

    phase 3 small molecule active

    1 trial

  14. PLACEBO OF VANCOMYCINE = NaCl 0.9% ( oral use ), Vancomycine Viatris 500 mg poudre pour solution pour perfusion

    Pari Pharma GmbH

    Patients hospitalized for allogeneic hematopoietic stem cell transplantation

    phase 3 small molecule active

    1 trial

  15. PLACEBO SOTAGLIFLOZIN, SOTAGLIFLOZIN

    LEXICON PHARMACEUTICALS, INC.

    Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy

    phase 3 small molecule active

    1 trial

  16. PLACEBO for GIVINOSTAT hydrochloride monohydrate (ITF2357) 10 mg/mL oral suspension, ITF2357

    Italfarmaco S.p.A.

    Duchenne muscular dystrophy (DMD)

    phase 3 small molecule active

    1 trial

  17. PLACEBO, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, INFLIXIMAB, DOMVANALIMAB

    AstraZeneca AB

    The target population of interest in this study is participants with locally advanced (Stage III), unresectable NSCLC, whose tumours express PD L1 TC β‰₯ 1% as assessed by a central reference laboratory using the VENTANA PD-L1 (SP263) IHC assay, and who did not progress after definitive platinum based cCRT.

    phase 3 small molecule active

    1 trial

  18. PLACEBO, Nicetile 500 mg polvere per soluzione orale

    Istituto Gentili S.r.l.

    amyotrophic lateral sclerosis

    phase 3 small molecule active

    1 trial

  19. PLASMA, Omniplasma 45-70 mg/ml oplossing voor infusie

    Disc Medicine

    Coagulation in pediatric cardiac surgery

    phase 3 small molecule active

    1 trial

  20. PLERIXAFOR, Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN, FILGRASTIM

    Vertex Pharmaceuticals (Australia) Pty.

    Transfusion-dependent Ξ²-thalassemia (TDT), Severe sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  21. PRAX-114

    Chongqing Precision Biotech Co., Ltd

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  22. PRAX-222

    Chongqing Precision Biotech Co., Ltd

    Voltage-gated sodium channel type II alpha subunit (SCN2A) developmental and epileptic encephalopathy (DEE)

    phase 3 small molecule active

    1 trial

  23. PRAX-562

    Chongqing Precision Biotech Co., Ltd

    SCN2A Encephalopathy

    phase 3 small molecule active

    1 trial

  24. PRAX-628, PRAX-628, PRAX-628, PRAX-628

    Chongqing Precision Biotech Co., Ltd

    Focal onset seizures or primary generalized tonic-clonic seizures.

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources